Neuropsychiatric Disorders

Neuropsychiatric disorders represent some of the most enigmatic conditions within the central nervous system, blending cognitive, emotional, and motor dysfunctions. At Muriphys, we approach these challenges with precision, offering tailored preclinical models and cutting-edge drug delivery systems designed to unravel the complexities of neuropsychiatric diseases.

Our state-of-the-art platforms provide comprehensive insights into the neural circuits, biomarkers, and behaviors underpinning disorders such as schizophrenia, anxiety, and dementias. By partnering with Muriphys, you gain access to world-class expertise that accelerates the development of novel therapeutics, bringing hope to millions affected by these conditions.

Disorders We Specialize In:

Schizophrenia
Schizophrenia’s multifaceted symptoms require innovative preclinical models that reflect the full spectrum of cognitive, sensory, and motor disturbances. Muriphys leverages intraparenchymal (IPa), intracerebroventricular (ICV), and intrathecal (IT) delivery systems to administer therapeutics directly to brain regions implicated in psychosis and cognitive dysfunction. Our behavioral tests assess learning, memory, and sensory gating, while EEG recordings provide biomarkers for neural network disruption and treatment efficacy. Read more.

Anxiety Disorders
Anxiety manifests through a complex interplay of neural circuits, often resistant to traditional pharmacology. Muriphys utilizes precise CNS delivery methods to target limbic and prefrontal regions. Behavioral assays, including open field, elevated maze, and shuttle box tests, measure anxiety responses, while electrophysiological recordings reveal disruptions in neural activity, guiding the development of next-generation anxiolytics.

Dementias
From Alzheimer’s and Lewy Body Dementia to Frontotemporal Dementia, Muriphys provides comprehensive preclinical tools to study cognitive decline. Our advanced IPa, ICV, and IT delivery platforms ensure targeted drug administration to the hippocampus, cortex, and broader CNS. Behavioral assays, such as Y-maze and novel object recognition, track cognitive performance, while EEG studies detect early neural degeneration, creating a full-spectrum assessment of therapeutic impact. Read More.

Why Muriphys for Neuropsychiatric Research?

• Targeted CNS Delivery: Our precision delivery systems enable localized drug administration to the regions most affected by neuropsychiatric disorders, ensuring high specificity and reproducibility.
• Comprehensive Behavioral Testing: From anxiety to cognitive impairment, our suite of assays mirrors the clinical presentations of neuropsychiatric disorders, providing critical endpoints for drug efficacy.
• Electrophysiology for Deeper Insights: EEG and EMG recordings track neural oscillations, revealing biomarkers that inform both disease progression and therapeutic response.
• Customized Research Programs: Neuropsychiatric disorders demand multifaceted approaches. Muriphys tailors every aspect of the study to reflect the specific pathophysiology of each condition, driving more precise and impactful results.

At Muriphys, we stand at the crossroads of neuroscience and innovation, equipping researchers with the tools necessary to transform neuropsychiatric disorder research.

Advance your neuropsychiatric research with Muriphys—where science, precision, and discovery converge.